【映恩生物啟動IPO輔導】《科創板日報》6日訊,映恩生物(Duality Biotherapeutics, Inc.)獲上市輔導備案登記,擬在A股IPO,輔導機構為中信證券。該公司專注于為癌癥和自身免疫性疾病患者研發新一代抗體偶聯藥物(ADC)。
特別聲明:以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布,本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.